Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 PEBL CAR T-cell therapy for R/R T-ALL
NCT05043571Phase 1Recruiting
- Sponsor
- National University Hospital
- Start
- Sep 2021
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD7 PEBL chimeric antigen receptor T cells in acute lymphoblastic leukemia (ALL) and lymphoma, sponsored by National University Hospital. Primary endpoint: Minimal Residual Disease Negativity by Flow Cytometry at 30 days. Started Sep 2021; status: recruiting.
02
Drugs
anti-CD7 PEBL chimeric antigen receptor T cells
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT05043571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043571.